The study found that the average healthcare cost of an unnecessary shock was $4470, and 42% of the patients captured in the data received an inappropriate shock. The group included 41% in Medicare.
For patients with heart disease, an implantable cardioverter defibrillator (ICD) can give a life-saving shock when it senses ventricular arrhythmia. However, unnecessary shocks—essentially, false alarms—can still trigger health costs that would best be prevented.
A study published this week in Circulation: Cardiovascular Quality and Outcomes found that the cost an unnecessary shock averaged $4470 per incident, compared with the average cost of $5592 for appropriate shocks, or those that were found to be necessary. The journal is an official publication of the American Heart Association.
Fortunately, researchers led by Mintu Turakhia, MD, MAS, of the Center for Digital Health at Stanford, say there’s a solution: ICDs, even older models, can be reprogrammed to deliver fewer false alarms, by waiting momentarily to see if ventricular arrhythmia resolves or avoiding shocks that are sent for unrelated causes.
Quality of care, Turakhia said, can no longer be measured only in terms of whether the right patients receive an ICD. The device must be programmed to trigger shocks only when necessary. “We have the technology to do that today,” he said in a statement.
Researchers developed their cost figures by analyzing records from 10,266 patients implanted with a Medtronic ICD in the United States from 2008 to 2010. Medtronic, which funded the study, provided data to be examined alongside patient health records. During the study period, 963 patients experienced 1885 shocks.
While the average age of the patients was 61, the oldest was 81, and 41% had Medicare coverage, which means the findings have implications for taxpayers as well. Of the group, 43% had appropriate shocks, 42% had inappropriate shocks, and 12% had both types.
The study also found:
Patients who turned out to have an unnecessary shock often received costly, invasive procedures, including cardiac catherization.
What causes unnecessary shocks? Turakhia explained that the device cannot examine a patient the way a doctor can, and older programming techniques can mistake a different heart rhythm for ventricular arrhythmia.
The current study was designed only to show whether patients received appropriate shocks, not whether the care received afterward was appropriate. But given the high cost of care from shocks regardless of whether they were needed, Turakhia said it’s safe to say eliminating the false alarms would spare patients unnecessary procedures and expense.
“Optimal device programming that reduces shock events (is) likely to decrease health care costs and improve patient health,” he said.
Reference
Turakhia MP, Zweibel S, Swain AL, Mollenkopf SA, Reynolds MR. Healthcare utilization and expenditures associated with appropriate and inappropriate implantable defibrillator shocks. Circ Cardiovasc Qual Outcomes. 2017; 10:e002210.
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Upadacitinib Shows Promise for Hard-to-Treat Crohn Disease
April 23rd 2025Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn disease, including those previously treated with advanced therapies, offering a potential second-line treatment option with a manageable safety profile.
Read More
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More